Durvalumab vs Empagliflozin

## Durvalumab vs Empagliflozin: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Empagliflozin**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Empagliflozin**: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Empagliflozin — 12.4 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Empagliflozin — C23H27ClO7.

**Molecular Weight**: Durvalumab — N/A; Empagliflozin — 450.9100 g/mol.

**Type**: Durvalumab — Antibody; Empagliflozin — Small molecule.